Lowering gamma prime fibrinogen levels to prevent blood clots in COVID-19 patients
Official title: Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
Funded at Gamma Therapeutics, INC. · NIH-10759950 · Data updated 2026-11-12
This study is testing a new treatment that aims to lower a specific type of fibrinogen in the blood that can cause dangerous clots, especially in people with COVID-19, by using tiny pieces of DNA to stop its production in liver cells, which could help reduce the risk of heart attacks and strokes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gamma Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | August 24, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $277,710 |
| NIH project number | 1R41HL170874-01 |
| Project ID | NIH-10759950 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with COVID-19 who are experiencing high levels of gamma prime fibrinogen and are at risk for thrombotic events.
✕Less likely to help
Patients who do not have COVID-19 or those with normal levels of gamma prime fibrinogen may not benefit from this research.
What this research studies
This research focuses on developing a new treatment to reduce levels of gamma prime fibrinogen (GPF), a variant of fibrinogen that can lead to dangerous blood clots, particularly in patients with COVID-19. The approach involves using antisense oligonucleotides, which are small pieces of DNA designed to bind to specific RNA molecules, preventing the production of GPF in liver cells. By lowering GPF levels, the research aims to reduce the risk of thrombotic events such as heart attacks and strokes in affected patients. The study will utilize human liver cell lines to test the effectiveness of these oligonucleotides in regulating GPF production.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of blood clots in COVID-19 patients, improving their overall health outcomes.
How similar studies have gone: While the approach of using antisense oligonucleotides is established, the specific application to gamma prime fibrinogen in the context of COVID-19 is novel and has not been extensively tested.
Where this research is happening
-
Gamma Therapeutics, INC.
Portland, United States Active
Researchers
- Principal investigator: Farrell, David Henry — Gamma Therapeutics, INC.
- Study coordinator: Farrell, David Henry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.